chang top
gilead report result last week underli beat core
ep expect new hiv drug biktarvi start see strong demand
like major driver share price go
forward rather declin revenu hepat case
sever prior quarter financi guidanc full year alter
base non-gaap tax rate accordingli fy core ep
estim rise slightli view gilead share remain unchang
believ under-valued base current busi
core earn although product would like quickest rout
re-rat
biktarvi over-deliv although would caution read
much number earli launch demand biktarvi look
strong hiv sale total flatter us payer mix sale
privat sector less heavili discount usual
possibl may need wait anoth coupl quarter see
land lie long term larg portion biktarvi sale
continu cannibalis gilead product peak sale
still end current portfolio leader genvoya
forecast global biktarvi sale
hepat market look much stabl consist
manag expect declin hepat sale line look like
final offer predict market split larg
gilead new patient start expect continu
declin slowli although note european patient dynam alreadi
appear flat
manag chang notabl result announc
came news ceo john milligan chairman john martin
former ceo leav compani end year
work gilead mani year compani also lost leader
commerci oper jame meyer retir februari
head norbert bischofberg left april
oper substanti chang leadership futur
suggest could delay possibl activ seem fair
continu success biktarvi support share next
month
chang made note
price target usd chang
buy chang
perform rel
compani base us
global biopharmaceut
profit loss summari
growth margin
gener sale peak gilead hepat
franchis steep declin creat disappoint
howev franchis long cash-gen tail
major part gilead busi drug treat hiv
remain strong compani success drive uptak
gilead pipelin larg ignor could sourc
upsid posit result forthcom
even kite acquisit share offer good
 option compani strong balanc sheet
valuat dcf-deriv
chang net debt
average cost debt
risk invest thesi
manag fail find deal excit investor enough get
share price move
price volum hepat driven even
competit hiv becom tougher expect competitor
success develop new drug becom challeng product
profit loss account
royalti contract revenu
sale
research develop
 sale
sell gener administr
 revenu
net tax
net incom attribut
net incom attribut
net incom attribut
net incom attribut
weight averag number share dilut million
cash equival
account receiv net allow
prepaid expens current asset
long term proport prepaid royalti
accru govern rebat
current portion long term debt oblig net
commit conting
equiti portion current redeem convert
total liabil equiti
total liabil equiti
total liabil equiti
total liabil equiti
net cash provid oper activ
net cash provid oper activ
net cash provid oper activ
net cash provid oper activ
purchas market secur
proce sale market secur
proce matur market secur
acquisit net cash acquir
net cash use invest activ
net cash use invest activ
net cash use invest activ
net cash use invest activ
proce debt financ net issuanc cost
proce convert note hedg
purchas convert note hedg
proce issuanc common stock
repurchas common stock
repay debt oblig
payment settl warrant
payment dividend
contribut non-controlling interest
net cash use financ actviti
net cash use financ actviti
net cash use financ actviti
net cash use financ actviti
effect fx cash cash equival
increas cash cash equival
cash equival begin
cash equival end
cash equival end
cash equival end
cash equival end
pleas note use research report subject condit restrict set forth gener inv
pleas note use research report subject condit restrict set forth gener invest
pleas note use research report subject condit restrict set forth gener inv
pleas note use research report subject condit restrict set forth gener inv
disclosur legal disclaim end document
